Trend
DailyDowntrend (starting)
4 hourStrong Bearish
1 hourBearish
15 minAscending Triangle
5 minStrong Bearish
Daily trend turns up above $21.45
Key levels
Resistance$13.76
Resistance$12.84
Support$11.85
Support$10.13
Latest news & SEC filings
AnalystLadenburg Thalmann keeps Buy rating on NovoCure, lifts target to $31
AnalystWedbush keeps Neutral rating on NovoCure, cuts price target to $19
All NVCR news →NovoCure is an oncology company whose Tumor Treating Fields therapy uses electric fields, applied by a wearable device, to interfere with cancer cell division. Its products include Optune Gio for glioblastoma, Optune Lua for non-small cell lung cancer and mesothelioma, and Optune Pax for pancreatic cancer. It sells across the United States, Europe, Japan and other markets, with most revenue from Optune Gio. It also licenses rights in Greater China to Zai Lab.
Based on the company's 10-K filed Feb 26, 2026.
Nasdaq · Healthcare
SEPT Low Target
$15.00
SEPT Mid Target
$20.00
SEPT High Target
$52.00
Analyst Consensus
$20.00
Thesis
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for NVCR.
Start Free Trial →Valuation Verdict
UNDERVALUED
Methods Used
Analyst Consensus
Fair Value
$20.00
37
Moat Score
NONE
4/9
Piotroski Score
0.5
Altman Z-Score
Insider Signal
SELLING
0 buys / 10 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Puri Michal Nath | officer | Sale | 660 | $9K | Nov 2, 2026 |
| Leonard Frank X | officer | Sale | 34,273 | $615K | Jun 4, 2026 |
| Stafford Kristin | director | Buy | 11,610 | - | Jun 3, 2026 |
| Ocean Allyson J | director | Buy | 11,610 | - | Jun 3, 2026 |
| Madden Martin J. | director | Buy | 11,610 | - | Jun 3, 2026 |
| Scannell Timothy J | director | Buy | 11,610 | - | Jun 3, 2026 |
| VERNON W ANTHONY | director | Buy | 11,610 | - | Jun 3, 2026 |
| Hung David | director | Buy | 11,610 | - | Jun 3, 2026 |
| LEUNG GABRIEL | director | Buy | 11,610 | - | Jun 3, 2026 |
| HILLEMAN JERYL L | director | Buy | 11,610 | - | Jun 3, 2026 |
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →Revenue YoY
8.3%
3yr Revenue CAGR
6.8%
EPS Growth YoY
21.79%
FCF Growth YoY
-9.3%
Revenue Trend
ACCELERATING
SEPT Investing tracks real-time dark pool institutional trades for NVCR, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 21:26:18 | $11.99 | 1,519 | $$18K | SELL |
| 21:00:22 | $11.99 | 1,289 | $$15K | SELL |
| 21:00:22 | $11.99 | 5,045 | $$60K | SELL |
| 20:58:55 | $11.98 | 2,000 | $$24K | SELL |
| 20:54:55 | $11.97 | 1,400 | $$17K | SELL |
5 dark pool trades shown · $$135K preview volume
Real-time institutional flow, block trades, and net positioning
SEPT Investing provides real-time options flow tracking for NVCR, including unusual sweep detection, block trades, and dealer positioning. Each trade shows strike, expiry, premium, implied volatility, and greek values for informed decision-making.
| Type | Strike | Expiry | DTE | Premium | Size | Trade |
|---|---|---|---|---|---|---|
| CALL | $13 | Dec 18 | 37 | $$75 | 1 | SWEEP |
1 options trades shown · 100% calls
Unusual activity, GEX levels, max pain, and dealer positioning
SEPT's Trading AI has generated a free, downloadable PDF research report for NovoCure Ltd (NVCR) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (4 articles analyzed), and SEC filing intelligence...
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →NovoCure Ltd (NVCR) is at $11.99, up 1.52% (+$0.18) at the Nov 11, 2026 close.
Latest NVCR news — Nov 10, 2026: Ladenburg Thalmann keeps Buy rating on NovoCure, lifts target to $31 · Nov 10, 2026: Wedbush keeps Neutral rating on NovoCure, cuts price target to $19
Novocure shares fell 3.54% to close at $12.53 after the FDA issued a not-approvable letter for the company's Optune Mya premarket approval application. The device, intended for adults whose non-small cell lung cancer had spread to the brain following stereotactic radiation, was turned down by US regulators, and the application will not move forward as submitted.
The average analyst price target for NVCR is $20.00, ranging from $15 to $52, based on 5 analysts. Latest: Wells Fargo maintains on Oct 30, 2026.
Analyst ratings for NVCR: 4 Buy, 3 Hold, 0 Sell — consensus Buy.
NVCR last reported on Oct 29, 2026: EPS -$0.09 vs -$0.23 expected — a beat of 61.7%.
NVCR does not currently pay a dividend.
Support: $11.85, $10.13. Resistance: $12.84, $13.76, $14.94.
Insider activity: SELLING, 0 buys and 10 sells in the last 90 days.
Nov 10, 2026: Ladenburg Thalmann keeps Buy rating on NovoCure, lifts target to $31 · Nov 10, 2026: Wedbush keeps Neutral rating on NovoCure, cuts price target to $19